Clinical Trial

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.
Trial Details
NCT Number NCT06221072
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Enrollment 1,360 participants
Start Date 2024-04-05
Primary Completion 2027-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-24